| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥296.1B | ¥288.4B | +2.7% |
| Operating Income | ¥-84.6B | ¥-54.2B | -56.0% |
| Profit Before Tax | ¥-149.5B | ¥-46.6B | -220.7% |
| Net Income | ¥-125.3B | ¥-48.4B | -159.0% |
| ROE | -20.5% | -7.1% | - |
FY2025 results show revenue of 296.1B yen (YoY +2.7%), operating loss of -84.6B yen (deterioration from -54.2B yen loss in prior year, representing -56.0% change), ordinary income of 7.1B yen (turning profitable from -15.4B yen loss, YoY +146.2%), and net loss of -125.3B yen (significant deterioration from -48.4B yen loss, YoY -159.0%). The company achieved modest top-line growth of 2.7% but experienced severe deterioration in operating profitability, with operating margin declining to -28.6%. While ordinary income turned positive due to non-operating factors including financial income of 9.9B yen, the bottom line deteriorated substantially due to finance costs of 74.8B yen and impairment losses of 11.6B yen. The company maintains a gross profit margin of 72.3%, indicating strong product economics, but this is overwhelmed by SG&A expenses of 152.2B yen (51.4% of revenue) and R&D expenses of 144.7B yen (48.8% of revenue). Cash and equivalents stood at 203.7B yen with equity ratio of 45.3%, providing near-term financial stability despite operating cash flow being negative at -26.7B yen.
Revenue increased 2.7% YoY to 296.1B yen, driven by commercialized products which grew to 201.4B yen from 162.5B yen (YoY +23.9%), while research and development revenue declined to 94.8B yen from 125.9B yen (YoY -24.7%). This shift indicates growing dependence on marketed products rather than development partnerships. Geographically, Japan revenue increased substantially to 179.7B yen from 140.6B yen (YoY +27.8%), becoming the dominant market at 60.7% of total revenue, while US revenue declined sharply to 48.9B yen from 79.5B yen (YoY -38.5%). Major customer concentration increased, with Medipal Holdings accounting for 85.6B yen (28.9% of revenue) and Shionogi Pharmaceutical contributing 43.3B yen (14.6% of revenue).
Operating loss expanded to -84.6B yen from -54.2B yen, with the deterioration primarily driven by increased SG&A expenses rising to 152.2B yen and sustained high R&D investment of 144.7B yen. Despite maintaining gross profit of 214.2B yen with a robust margin of 72.3%, the combined burden of SG&A and R&D expenses totaling 296.9B yen resulted in significant operating losses. The gap between ordinary income (7.1B yen profit) and operating loss (-84.6B yen) of 91.7B yen reflects the impact of financial income 9.9B yen, finance costs -74.8B yen, other income 16.6B yen, and other expenses -18.4B yen. Non-recurring factors include impairment losses of 11.6B yen and bond modification losses of 46.5B yen recorded during the period. The substantial divergence between ordinary income and net loss (-125.3B yen) of 132.4B yen is explained by tax effects and these extraordinary charges. Pre-tax loss of -149.5B yen improved to net loss of -125.3B yen due to a tax benefit of 24.2B yen.
The company exhibits a "revenue up, profit down" pattern, where modest revenue growth failed to translate into profitability improvement due to the fixed cost structure of high R&D and SG&A spending overwhelming incremental gross profit gains.
The company operates as a single pharmaceutical segment, therefore segment-level operating profit analysis is not applicable. The business generates revenue from two categories: commercialized products (201.4B yen, 68.0% of revenue) and research and development partnerships (94.8B yen, 32.0% of revenue). The commercialized products category represents the core revenue driver with stronger year-over-year growth momentum.
[Profitability] Operating margin of -28.6% deteriorated from -18.8% in the prior year, reflecting 9.8 percentage point decline. Gross profit margin remained stable at 72.3%, demonstrating strong product-level economics. ROE of -19.3% compares unfavorably to positive territory, driven by net loss of -125.3B yen against average equity base of approximately 647.6B yen. The company recorded negative EBITDA margin with operating loss exceeding depreciation and amortization of 43.7B yen. [Efficiency] Total asset turnover of 0.22x indicates low asset utilization, with revenue of 296.1B yen generated from average assets of approximately 1,431.5B yen. Inventory turnover days extended to 503 days, calculated from inventories of 112.9B yen against cost of sales of 82.0B yen, signaling potential inventory management challenges. Accounts receivable collection period stood at 95 days, reflecting trade receivables of 77.3B yen relative to revenue run rate. The cash conversion cycle of 264 days highlights working capital intensity. [Financial Health] Equity ratio of 45.3% with total equity of 610.0B yen against total assets of 1,347.9B yen indicates moderate financial stability. Current ratio calculation is constrained by unavailable current liabilities detail, though cash and deposits of 203.7B yen provide liquidity buffer. Debt-to-equity ratio of 0.35x reflects long-term loans of 211.1B yen against equity base. Net debt position is negative 7.4B yen when considering cash of 203.7B yen against interest-bearing debt of 211.1B yen. The balance sheet carries substantial intangible assets of 492.3B yen (36.5% of total assets) and goodwill of 258.4B yen (19.2% of total assets), representing significant impairment risk exposure. [Cash Quality] Operating cash flow of -26.7B yen against net loss of -125.3B yen yields an operating CF to net income ratio of 0.21x, indicating poor cash generation relative to reported earnings. Interest coverage is negative given operating losses, with finance costs of 74.8B yen and interest paid of 5.3B yen creating significant financial burden. Free cash flow of 27.6B yen arose from negative operating CF of -26.7B yen offset by positive investing CF of 54.3B yen, which included asset sale proceeds of 20.8B yen from investment securities.
Operating cash flow of -26.7B yen improved from -77.2B yen in the prior year, representing 65.4% reduction in cash outflow. The operating CF subtotal before working capital changes was -42.3B yen, starting from pre-tax loss of -149.5B yen adjusted for non-cash items including depreciation and amortization of 43.7B yen, share-based compensation of 19.5B yen, impairment losses of 11.6B yen, and bond modification losses of 46.5B yen. Working capital changes provided partial offset with accounts payable increasing 29.7B yen, though this benefit was consumed by inventory increase of 24.6B yen and accounts receivable increase of 10.4B yen. Interest paid of 5.3B yen and income taxes paid of 2.4B yen represented additional operating outflows, partially offset by tax refunds of 12.5B yen. Investing cash flow generated 54.3B yen primarily from sale of investment securities yielding 20.8B yen and time deposit maturities of 39.5B yen, while capital expenditures totaled 4.5B yen and intangible asset acquisitions 1.8B yen. Financing cash flow consumed -160.3B yen, driven by long-term debt repayments of 58.0B yen, bond redemptions of 48.4B yen, bond modification payments of 45.0B yen, and lease payments of 8.9B yen. Foreign exchange effects contributed positively at 13.6B yen. The net result was cash and equivalents declining 119.0B yen to 203.7B yen from 322.7B yen. The positive free cash flow of 27.6B yen should be viewed cautiously as it relied on asset sales and deposit maturities rather than sustainable operating cash generation, with the core operating activities consuming cash.
Operating income of -84.6B yen versus ordinary income of 7.1B yen reflects net non-operating contribution of 91.7B yen. The composition includes financial income of 9.9B yen and other income of 16.6B yen, totaling 26.5B yen in positive non-operating items, offset by finance costs of 74.8B yen and other expenses of 18.4B yen. Finance costs represent 25.3% of revenue, comprising a significant burden on profitability. The fair value change in contingent consideration liability of 19.4B yen recorded as expense and bond modification loss of 46.5B yen are non-recurring in nature. The divergence from ordinary income to net loss involves pre-tax loss of -149.5B yen benefiting from income tax benefit of 24.2B yen, yielding net loss of -125.3B yen. Operating cash flow of -26.7B yen falling short of net loss magnitude suggests earnings quality concerns, though the absolute operating CF to net income ratio calculation is distorted by both figures being negative. The positive aspect is that depreciation and amortization of 43.7B yen provides substantial non-cash buffer. Research and development tax credits of 16.1B yen represent recurring operational benefit. The composition of impairment losses of 11.6B yen and substantial finance costs relative to operating base indicates financial structure challenges. Overall earnings quality is constrained by negative operating profitability, high intangible asset concentration at 55.7% of total assets (intangibles plus goodwill), and negative operating cash generation, though these are partially expected characteristics of a development-stage pharmaceutical company with significant R&D investment of 144.7B yen representing 48.8% of revenue.
No formal quantitative guidance for future periods is provided in the disclosed materials. The company notes in forecast-related commentary that forward-looking statements are based on currently available information and reasonable assumptions, with actual results potentially differing materially. The fiscal year represents full-year results ending December 31, 2025, therefore quarterly progress rate analysis is not applicable. Without disclosed guidance targets, assessment of forecast achievement progress or revision analysis cannot be performed.
The company forecasts zero dividend for the fiscal year, maintaining no dividend policy. With net loss of -125.3B yen, the dividend payout ratio is not calculable. No share repurchases were executed during the period based on treasury stock remaining constant at 20 million yen. The total shareholder return ratio is effectively zero percent given absence of both dividends and buybacks. The company's financial position with negative operating cash flow of -26.7B yen, net loss, and need to preserve cash resources of 203.7B yen for operations and debt servicing provides clear rationale for suspension of shareholder distributions. Retained earnings deficit of -175.5B yen represents an accumulated loss position, legally constraining dividend capacity under Japanese corporate law which requires positive retained earnings for dividend distributions.
Clinical development and regulatory approval risks represent the primary business risk, with R&D expenses of 144.7B yen (48.8% of revenue) creating significant capital commitment to pipeline programs whose success is uncertain. Pipeline setbacks or regulatory delays could materially impact future revenue generation capacity and asset valuations, particularly given intangible assets of 492.3B yen and goodwill of 258.4B yen representing 55.7% of total assets. Customer concentration risk is elevated with top customer Medipal Holdings representing 85.6B yen or 28.9% of total revenue and Shionogi Pharmaceutical contributing 43.3B yen or 14.6%, creating revenue volatility exposure if these relationships deteriorate. Geographic concentration increased substantially with Japan revenue rising to 60.7% of total revenue at 179.7B yen while US revenue declined 38.5% to 48.9B yen, reducing geographic diversification and increasing exposure to single-market dynamics. Financial structure risk stems from finance costs of 74.8B yen consuming 25.3% of revenue, with long-term debt of 211.1B yen and bonds of 260.8B yen creating refinancing risk and interest burden that amplifies operating losses. Working capital deterioration is evidenced by inventory increasing 24.6B yen and accounts receivable rising 10.4B yen while inventory turnover extended to 503 days, indicating potential obsolescence risk and cash conversion challenges that constrain liquidity despite current cash position of 203.7B yen.
[Industry Position] (Reference - Proprietary Analysis)
Nexera Pharma operates in the pharmaceutical development sector characterized by high R&D intensity and extended cash burn periods prior to product commercialization. The company's financial profile reflects typical early-to-mid stage biotech characteristics with R&D expense ratio of 48.8% substantially exceeding industry norms for mature pharmaceutical companies but aligned with development-focused peers. Operating margin of -28.6% positions unfavorably relative to established pharmaceutical companies but represents expected performance for companies in transition from development to commercial operations. The gross margin of 72.3% demonstrates strong product-level profitability potential consistent with specialty pharmaceutical economics. Equity ratio of 45.3% provides moderate balance sheet strength, though below the 60%+ ratios typical of cash-rich mature pharmaceutical companies. The company's intangible asset concentration at 55.7% of total assets (including goodwill) is elevated compared to diversified pharmaceutical portfolios but reflects the intellectual property-centric nature of drug development businesses. ROE of -19.3% is not meaningful for comparison given negative earnings, but represents underperformance relative to industry benchmarks where profitable pharmaceutical companies typically achieve ROE in the 10-25% range. The shift toward commercialized product revenue increasing 23.9% YoY while R&D partnership revenue declined 24.7% suggests progress toward revenue model maturation, though operating profitability remains distant given the fixed cost structure requiring revenue scale exceeding 300B yen to approach breakeven based on current cost structure.
※ Industry: Pharmaceutical Development, Comparison: Historical performance and sector characteristics, Source: Proprietary analysis
Revenue composition shift toward commercialized products increasing to 68.0% of total revenue from 56.4% in prior year demonstrates business model progression from pure development to commercial-stage operations, with launched products growing 23.9% YoY to 201.4B yen indicating market traction for approved therapies. This evolution represents structural improvement in revenue sustainability compared to partnership-dependent models. Operating loss expansion to -84.6B yen from -54.2B yen despite revenue growth highlights the challenge of fixed cost absorption, with combined SG&A and R&D expenses of 296.9B yen exceeding gross profit of 214.2B yen by 82.7B yen, indicating breakeven revenue threshold likely exceeds 400B yen under current cost structure assumptions. Working capital deterioration evidenced by inventory days extending to 503 days and accounts receivable days at 95 days, combined with negative operating cash flow of -26.7B yen, signals operational execution challenges in converting revenue growth into cash generation, requiring management attention to supply chain optimization and collection processes. Financial structure sustainability appears adequate near-term with cash and deposits of 203.7B yen covering short-term needs, but interest burden of 74.8B yen in finance costs consuming 25.3% of revenue creates structural profitability headwind requiring either revenue scale expansion or debt restructuring to achieve sustainable economics. The positive free cash flow of 27.6B yen relied on asset monetization of 20.8B yen from investment securities and deposit releases rather than core operating cash generation, indicating the underlying business consumed 26.7B yen in operating activities and sustainability depends on either operational improvement or capital market access. Geographic and customer concentration increasing with Japan revenue rising to 60.7% of total and top two customers representing 43.5% of revenue creates revenue stability risk, though also may reflect strategic focus enabling operational efficiency gains through concentrated market development efforts.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.